Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
F Ye, S Dewanjee, Y Li, NK Jha, ZS Chen, A Kumar… - Molecular cancer, 2023 - Springer
Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …
heterogeneity of this disease presents a big challenge in its therapeutic management …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
A Rizzo, V Mollica, V Tateo, E Tassinari… - Cancer Immunology …, 2023 - Springer
Background The antitumor efficacy of immune checkpoint inhibitors (ICIs) has increasingly
emerged during the last few years. However, there is a need to identify the safety profile of …
emerged during the last few years. However, there is a need to identify the safety profile of …
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives
X Shi, X Wang, W Yao, D Shi, X Shao, Z Lu… - Signal transduction and …, 2024 - nature.com
Metastasis remains a pivotal characteristic of cancer and is the primary contributor to cancer-
associated mortality. Despite its significance, the mechanisms governing metastasis are not …
associated mortality. Despite its significance, the mechanisms governing metastasis are not …
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab after progression on cyclin-dependent Kinase 4/6 Inhibitor and Aromatase inhibitor for …
PURPOSE Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important
component of treatment for hormone receptor–positive/human epidermal growth factor …
component of treatment for hormone receptor–positive/human epidermal growth factor …
Immunotherapy approaches for breast cancer patients in 2023
Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis,
harnesses the power of the immune system to treat cancer, with unique potential for a …
harnesses the power of the immune system to treat cancer, with unique potential for a …
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
AC Watt, S Goel - Breast Cancer Research, 2022 - Springer
Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an
established standard of care for patients with advanced hormone receptor-positive breast …
established standard of care for patients with advanced hormone receptor-positive breast …
CircPVT1 promotes ER‐positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS
J Yi, L Wang, G Hu, Y Zhang, J Du, J Ding, X Ji… - The EMBO …, 2023 - embopress.org
The molecular mechanisms underlying estrogen receptor (ER)‐positive breast
carcinogenesis and endocrine therapy resistance remain incompletely understood. Here …
carcinogenesis and endocrine therapy resistance remain incompletely understood. Here …
Immunotherapy in breast cancer: an overview of current strategies and perspectives
V Debien, A De Caluwé, X Wang, M Piccart-Gebhart… - NPJ breast …, 2023 - nature.com
Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …
enhancement against breast cancer. In triple-negative breast cancer, the combination of …